Egenolf et al., 2011 - Google Patents
Development of a murine model of lymph node metastases suitable for immunotoxicity studiesEgenolf et al., 2011
- Document ID
- 7788838758122716642
- Author
- Egenolf D
- Rafferty P
- Brosnan K
- Walker M
- Jordan J
- Makropoulos D
- Kavalkovich K
- Watson S
- Johns L
- Volk A
- Bugelski P
- Publication year
- Publication venue
- Journal of Pharmacological and Toxicological Methods
External Links
Snippet
INTRODUCTION: Immunosuppressive drugs are associated with an increased risk of infections and in some cases neoplasia, particularly non-melanoma skin cancers. This paper describes the development of a model to test the effects of immunosuppressive drugs …
- 238000011161 development 0 title abstract description 9
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6712701B2 (en) | Pharmaceutical composition for treating cancer | |
| Brunner-Weinzierl et al. | CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy | |
| Oda et al. | A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia | |
| Rowshanravan et al. | CTLA-4: a moving target in immunotherapy | |
| AU2017219415B2 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| Mracsko et al. | Antigen dependently activated cluster of differentiation 8-positive T cells cause perforin-mediated neurotoxicity in experimental stroke | |
| Maier et al. | Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28−/− mice | |
| US11207393B2 (en) | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses | |
| Ochando et al. | Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells | |
| Chen et al. | Pik3ip1 is a negative immune regulator that inhibits antitumor T-cell immunity | |
| Karimi et al. | NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT | |
| US20090202544A1 (en) | Methods of Treating Diseases by Targeting Silt3 | |
| CN106573976B (en) | anti-CD 84 antibodies, compositions comprising the antibodies, and uses thereof | |
| US20080181864A1 (en) | Methods and products related to metabolic interactions in disease | |
| Ravindranathan et al. | Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma | |
| US20240368247A1 (en) | Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists | |
| Mezzapelle et al. | CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma | |
| AU768656B2 (en) | Methods and products related to metabolic interactions in disease | |
| Camirand et al. | CD45 ligation expands Tregs by promoting interactions with DCs | |
| KR20220101151A (en) | Compositions and methods for immunotherapy | |
| JP2003503319A (en) | Methods and products for manipulating uncoupled protein expression | |
| Jiang et al. | Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells | |
| Egenolf et al. | Development of a murine model of lymph node metastases suitable for immunotoxicity studies | |
| Cayssials et al. | Chronic myeloid leukemia: Immunobiology and novel immunotherapeutic approaches | |
| Li et al. | Anti-CCL25 antibody prolongs skin allograft survival by blocking CCR9 expression and impairing splenic T-cell function |